Published in F1000Prime Rep on October 01, 2014
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 9.35
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology (2010) 8.11
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev (2007) 6.79
Inflammasomes in health and disease. Nature (2012) 6.75
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2013) 4.46
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology (2014) 4.36
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med (2006) 4.36
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med (2000) 3.97
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med (2013) 3.35
Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol (2014) 3.26
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology (2014) 3.23
Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology (2009) 3.20
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A (2006) 3.05
Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med (2001) 2.95
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology (2004) 2.77
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol (2012) 2.52
Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology (2004) 2.44
GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.41
Bacterial infection in the pathogenesis of variceal bleeding. Lancet (1999) 2.35
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Angiogenesis in liver disease. J Hepatol (2008) 2.31
Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol (2014) 2.29
Propranolol--a medical treatment for portal hypertension? Lancet (1980) 2.27
Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis (2009) 2.22
Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18
The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology (2002) 2.17
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol (2009) 2.06
Therapy for hepatitis C--the costs of success. N Engl J Med (2014) 1.96
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol (2002) 1.92
Interactions between the intestinal microbiome and liver diseases. Gastroenterology (2014) 1.92
CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut (2014) 1.91
Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology (2009) 1.84
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut (2012) 1.83
Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol (2004) 1.81
Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann Intern Med (1992) 1.80
Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther (2009) 1.74
Central blood volume in cirrhosis: measurement with radionuclide angiography. Hepatology (1994) 1.71
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
Inflammasomes in liver diseases. J Hepatol (2012) 1.67
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology (1996) 1.66
Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med (2014) 1.64
NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int (2011) 1.63
Macrophage heterogeneity in liver injury and fibrosis. J Hepatol (2014) 1.63
Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol (2011) 1.62
Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology (2011) 1.61
Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology (2002) 1.60
Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology (1998) 1.57
PROPHYLACTIC PORTACAVAL ANASTOMOSIS IN CIRRHOTIC PATIENTS WITH ESOPHAGEAL VARICES: A PROGRESS REPORT OF A CONTINUING STUDY. N Engl J Med (1965) 1.55
Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology (2004) 1.55
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. Aliment Pharmacol Ther (2011) 1.54
Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut (2011) 1.52
TIPS: 25 years later. J Hepatol (2013) 1.51
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology (2009) 1.49
Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int (2008) 1.46
The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology (1982) 1.44
A metagenomic insight into our gut's microbiome. Gut (2012) 1.43
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol (2001) 1.38
Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev (2010) 1.38
Inflammasomes: far beyond inflammation. Nat Immunol (2012) 1.38
Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology (2005) 1.34
Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol (2013) 1.33
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A (2001) 1.31
Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal (2005) 1.31
Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology (1999) 1.29
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology (2012) 1.29
Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair (2013) 1.27
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology (2001) 1.25
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Mechanisms of extrahepatic vasodilation in portal hypertension. Gut (2008) 1.23
Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.23
Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res (2010) 1.22
Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology (2010) 1.20
Genetic determinants of alcoholic liver disease. Gut (2011) 1.19